First Published, Prospective, International, Observational Study of a NOAC in NVAF NVAF
Non-valvular atrial fibrillation (= NVAF). The term NVAF is restricted to cases in which atrial fibrillation occurs in the absence of rheumatic mitral stenosis or a prosthetic heart valve.
Patients2

Objective

  • Evaluate major bleeding and stroke or systemic embolism in NVAF NVAF
    Non-valvular atrial fibrillation (= NVAF). The term NVAF is restricted to cases in which atrial fibrillation occurs in the absence of rheumatic mitral stenosis or a prosthetic heart valve.
    patients in real world clinical settings, ranging from primary care practices to cardiologists’ offices and hospitals1

Study design

  • A large, prospective, observational, single-arm, non-interventional study to evaluate the safety and efficacy of Xarelto® in the real world1
  • Patients were enrolled from June 2012 to December 2013 from 311 centres in Europe, Canada and Israel1

Population

  • 6,784 adults with NVAF newly receiving once-daily Xarelto for prevention of stroke and systemic embolism for NVAF were followed for 1 year, or 30 days following permanent treatment discontinuation1

XANTUS: CHADS2-scores

XANTUS: CHADS2-scores

NVAF, non-valvular atrial fibrillation. AF AF
Atrial fibrillation (= AF). A heart rhythm disorder where chambers in the upper heart (atria) beat more rapidly than those in the lower section of the heart. Blood is not pumped out of the upper chambers completely during beating, and may pool and form a clot. A stroke results if a section of clot dislodges from the upper chambers and becomes lodged in the brain.
, atrial fibrillation. CHF, congestive heart failure. TIA TIA
Transient ischaemic attack (= TIA). Also known as a ‘mini stroke’. This is caused by a temporary disruption in the blood supply to part of the brain.
, transient ischaemic attack. LVEF LVEF
Left ventricular ejection fraction (= LVEF). The measurement of how much blood is being pumped out of the left ventricle of the heart.
, left ventricular ejection fraction. CrCl, creatinine clearance. CHADS2-score is used to estimate stroke risk in patients with NVAF. aOr LVEF <40%. bFor Xantus patients, figure related to only age >75 years old. cFor Xantus patients, this also could have included prior systemic embolism. dModerate renal impairment was defined as CrCl 30–49 ml/min in ROCKET AF. e34.4% of patients had unknown CrCl values. fModerate to severe renal impairment was defined as CrCl <50 ml/min in Xantus. gXarelto is only approved for stroke prevention in NVAF patients with one or more risk factors.

  • XARELTO is evidenced across the full CHADS2-scores risk spectrum.1,2
    XANTUS real world evidence reflects the patients seen frequently in general practice.